drugset / Trial / NCT06274554
Testing the Role of Anti-fungal Therapy in Improving the Response to Therapies for Crohn's Disease
Phase 3
Recruiting
120 enrolled
Weill Medical College of Cornell University
The Leona M. and Harry B. Helmsley Charitable Trust · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
The goal of this clinical trial is to learn about the effects of fluconazole in patients who plan to start or are currently undergoing standard of care treatment and plan to dose-escalate an IL-23 therapy for their Crohn's disease. The main question it aims to assess is whether or not patient response to IL-23 therapies improve when simultaneously treated with fluconazole.
Timeline
- Start
- 2024-10-04
- Primary completion
- 2028-12
- Completion
- 2029-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fluconazole | Small molecule | 100 mg | Oral |
| Background | Guselkumab | Monoclonal antibody | — | — |
| Background | Risankizumab | Monoclonal antibody | — | — |
| Background | Ustekinumab | Monoclonal antibody | — | — |